Drug intelligence / Profile preview

oNKo-002

Development stage: Preclinical
Lead developer: oNKo-innate
Modality: Vaccines & Immunotherapeutics

Overview

oNKo-002 is a novel biologic immunotherapy in preclinical development by oNKo-innate. It is designed to enhance the anti-cancer activity of Natural Killer (NK) and T cells by targeting a checkpoint pathway specific to these cell types. The precise molecular target remains undisclosed, but it was identified using a CRISPR screening platform developed by the company. The drug aims to boost immune-mediated tumor cell killing, representing an innovative approach within cancer immunotherapy[2][1].

Beyond the preview

Go deeper on oNKo-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oNKo-002.

Explore the full profile